Abstract
Curcumin and paclitaxel are widely used as anti-tumor hydrophobic model drugs for the designation of smart tumor-targeting nanocarriers and the study of the correlation between structural characteristics of nanoparticles and in vivo therapeutic efficacy. Various signaling pathways on cell growth and proliferation have been comprehensively studied in vitro and in vivo under the action of curcumin and paclitaxel nanoparticles. In this paper, we prepared EGFR-targeted GE11 peptide-modified curcumin and paclitaxel compound liposomes (CUR-PTX@GE11-L). The tumor suppression mechanism of CUR-PTX@GE11-L is observed from the aspects of drug release behavior, changes of cell morphology, liver retention, and tumor-targeting efficiency. We hope it can provide a new vision for the rational construction of smart nanoscale drug delivery system through the observation of cytotoxic effects of CUR-PTX@GE11-L, especially on the cellular morphology change.Graphical
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
